Sector News

Eli Lilly is expanding its global reach: CEO

October 20, 2016
Life sciences

Eli Lilly is expanding its international operations to target diabetes and tuberculosis in areas without access to proper treatment, CEO John Lechleiter said Tuesday.

Lechleiter told CNBC’s “Squawk Box” the pharmaceutical giant will expand a program already in place to provide parts of Brazil, Mexico, South Africa, and India with treatment for Type 2 diabetes.

Lechleiter, who is stepping down as CEO, president and chairman this year, said the company hopes to reach 30 million people on an annual basis by the year 2030.

Lechleiter, who will stay on as nonexecutive chairman, is being replaced by Senior Vice President Dave Ricks. Lechleiter said Ricks, a longtime employee, will be the “perfect person” to lead the company through the numerous product launches it expects by 2023.

The pharmaceutical giant reports earnings on Oct. 25. Analysts expect $3.59 earnings per share, according to Thomson Reuters.

Source: CNBC

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach